Recent regulatory data reveals a significant upward trajectory in UK pharmaceutical parallel import activity. The MHRA granted 342 parallel import licences in 2026, representing a 15 percent increase from 298 licences approved in 2025. This growing trend underscores the UK’s increasing reliance on supply chain flexibility mechanisms to maintain medicine availability following Brexit.
The year-on-year growth in parallel import licences reflects the persistent challenges created by post-Brexit regulatory separation from European pharmaceutical systems. These licences permit the importation of medicines already authorised in EU member states, enabling rapid response to supply disruptions and shortages. The data demonstrates that parallel importation has become an indispensable regulatory tool for managing the complexity of UK-EU pharmaceutical relationships. Health authorities and pharmaceutical stakeholders continue to depend on this mechanism to ensure patients maintain uninterrupted access to essential medicines across diverse therapeutic categories.
Read the full article on GMJ Newsroom.
Was this article helpful?
